Improving antibiotics for treating difficult mycobacterial infections
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics
This study is working on new antibiotics to help fight tough infections like tuberculosis, aiming to make treatments more effective for people who struggle with these stubborn bacteria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Southern Methodist University NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-10890839 on NIH RePORTER |
What this research studies
This research focuses on developing new carbapenem antibiotics specifically designed to combat mycobacterial infections, including tuberculosis and other nontuberculous mycobacteria. The approach involves creating antibiotics with unique structural modifications to enhance their effectiveness against these challenging bacteria, which often resist traditional treatments. By understanding the mechanisms of resistance and targeting specific bacterial processes, the research aims to improve treatment outcomes for patients suffering from these infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with mycobacterial infections, such as tuberculosis or nontuberculous mycobacteria.
Not a fit: Patients with infections caused by bacteria other than mycobacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibiotic treatments for patients with severe mycobacterial infections, potentially reducing treatment duration and improving recovery rates.
How similar studies have performed: While the approach of modifying carbapenem antibiotics is innovative, previous research has shown promise in enhancing antibiotic effectiveness against resistant bacteria, suggesting potential for success.
Where this research is happening
Dallas, United States
- Southern Methodist University — Dallas, United States (Active)
Researchers
- Principal investigator: Buynak, John D — Southern Methodist University
- Study coordinator: Buynak, John D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.